Novel Quinazolinone Derivatives: Potential Synthetic Analogs for the Treatment of Glaucoma, Alzheimer's Disease and Diabetes Mellitus
Chemistry & Biodiversity · 2023
DOI: 10.1002/cbdv.202301134 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2023. Verfasst von Feyzi Sinan Tokalı und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Material and Material Processing Technologies, Kars Vocational School, Kafkas University, Kars, 36100, Turkiye. Hauptthemen laut MEDLINE: Alzheimer Disease, Quinazolinones, Cholinesterase Inhibitors, Glaucoma. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Scientific Research Projects Commission of Bartın University.
Themen: Diabetes mellitus, Demenz
Abstract (Originalsprache)
Quinazolinones, which represent an important part of nitrogen‐containing six‐membered heterocyclic compounds, are frequently used in drug design due to their wide biological activity properties. Therefore, the novel quinazolinones were synthesized from the reaction of acylated derivatives of 4‐hydroxy benzaldehyde with 3‐amino‐2‐alkylquinazolin‐4( 3H )‐ones with good yields (85–94 %) and their structures were characterized using Fourier‐transform Infrared (FT‐IR), Nuclear Magnetic Resonance ( 1 H‐NMR, 13 C‐NMR), and High‐Resolution Mass Spectroscopy (HR‐MS). As the application of the synthesized compounds, their inhibition properties of the synthesized compounds on α‐Glucosidase (α‐Glu), Acetylcholinesterase (AChE), Butyrylcholinesterase (BChE), and Carbonic anhydrase I–II (hCA I–II) metabolic enzymes were investigated. All compounds showed inhibition at nanomolar level with the K i values in the range of 12.73±1.26–93.42±9.44 nM for AChE, 8.48±0.92–25.84±2.59 nM for BChE, 66.17±5.16–818.06±44.41 for α‐Glu, 2.56±0.26–88.23±9.72 nM for hCA I, and 1.68±0.14–85.43±7.41 nM for hCA II. Molecular docking study was performed to understand the interactions of the most potent compounds with corresponding enzymes. Also, absorption, distribution, metabolism, excretion, and toxicity (ADME/T) properties of the compounds were investigated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Material and Material Processing Technologies, Kars Vocational School, Kafkas University, Kars, 36100, Turkiye.
- Department of Biotechnology, Faculty of Science, Bartin University, Bartin, 74100, Turkiye.
- Departmentof Plant and Animal Production, Sivas Technical Sciences Vocational School, Sivas Cumhuriyet University, 58140, Sivas, Turkiye.
- Department of Chemistry, Faculty of Sciences, Atatürk University, 25240-, Erzurum, Turkiye.
ORCID-Profile: Feyzi Sinan Tokalı, Parham Taslimi, Burak Tuzun, Ahmet Karakuş, Nastaran Sadeghian, İlhami Gulçin
Förderung
- Scientific Research Projects Commission of Bartın University
Zitieren
APA
Tokalı, F. S., Taslimi, P., Tuzun, B., Karakuş, A., Sadeghian, N., & Gulçin, İ. (2023). Novel Quinazolinone Derivatives: Potential Synthetic Analogs for the Treatment of Glaucoma, Alzheimer's Disease and Diabetes Mellitus. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202301134
Vancouver
Tokalı FS, Taslimi P, Tuzun B, Karakuş A, Sadeghian N, Gulçin İ. Novel Quinazolinone Derivatives: Potential Synthetic Analogs for the Treatment of Glaucoma, Alzheimer's Disease and Diabetes Mellitus. Chemistry & Biodiversity. 2023. doi:10.1002/cbdv.202301134
BibTeX
@article{Tokal2023,
author = {Tokalı, Feyzi Sinan and Taslimi, Parham and Tuzun, Burak and Karakuş, Ahmet and Sadeghian, Nastaran and Gulçin, İlhami},
title = {Novel Quinazolinone Derivatives: Potential Synthetic Analogs for the Treatment of Glaucoma, Alzheimer's Disease and Diabetes Mellitus},
journal = {Chemistry & Biodiversity},
year = {2023},
doi = {10.1002/cbdv.202301134}
}
EUVIMED